Mink Therapeutics Stock Earnings Reports

Mink Therapeutics (IMTT platform) provided an operational and scientific update focused on advancing their off-the-shelf invariant NKT (iNKT) cell therapy agenT-797 across oncology and severe pulmonary indications. Key investor takeaways: (1) Clinical advancement — the company has initiated a randomized Phase II trial in severe acute lung injury/ARDS (1:1 randomization; Phase II portion ~90 patients) with a seamless Phase II/III design. Endpoints include overall survival, ventilator-free days and ICU days; preliminary readouts are expected in the second half of this year. (2) Biology/translational evidence — presentations at recent conferences show the same unmodified donor-derived product produces context-dependent immune outputs (TH1/tumor-killing in cancer vs. restoration/anti-inflammatory signaling in ARDS), suggesting dynamic, disease-adaptive activity. (3) Safety and experience — ~100 patients treated to date with a favorable safety profile and emerging reproducible biological and clinical signals, including prolonged survival in a refractory gastric cancer cohort. (4) Commercial/operational positioning — off-the-shelf, cryopreserved product that requires no HLA matching or preconditioning, scalable donor-derived manufacturing, distribution logistics validated (including use in Ukraine), and partnerships (including ImmunityBio and a pediatric-targeted TCR program) that provide non-dilutive support. (5) Financials/runway — Q1 cash balance of ~$9.5M after note repayment; management states current cash provides at least ~12 months of runway inclusive of launching and executing the randomized trial; Q1 net loss ~$2.7M. Overall, the company is positioning for fast clinical readouts in ARDS while continuing translational oncology work and emphasizing capital-efficient execution and scalable manufacturing.